TY - JOUR
T1 - Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013
AU - Agrawal, Abhinav
AU - Agarwal, Abhishek
AU - Mehta, Dhruv
AU - Sikachi, Rutuja R.
AU - Du, Doantrang
AU - Wang, Janice
N1 - Funding Information:
The National Inpatient Sample (NIS) database was used to obtain a population-based estimate of national trends for CF. The NIS database is a tool developed as a part of the Healthcare Cost and Utilization Project (HCUP), and is sponsored by the Agency for Healthcare Research and Quality. The NIS database is the largest publicly available all-payer inpatient care database in the United States. It is designed to approximate a 20% sample of United States community (nonfederal) hospitals, and is organized according to geographic region, hospital ownership, location, teaching status, and number of beds, among other characteristics. The 2003 NIS database contains a total of approximately 8 million records. The 2013 NIS database contains a total of about 7.1 million records drawn from 44 states and includes information from 4363 hospitals. A comprehensive synopsis on NIS data is available at http://www.hcup-us.ahrq.gov. The immense size of the NIS database provides an exceptional sample representation of the general US population. In order to identify cases of CF, the NIS database was queried for hospital data on all discharges with ICD-9-CM primary diagnosis codes of 277.00-277.09 (CF and manifestations associated with CF) from 2003 to 2013. The NIS database provides administrative data for analysis and does not include patient-specific clinical data.
PY - 2017
Y1 - 2017
N2 - Cystic fibrosis (CF) is a multisystem autosomal recessive genetic disorder with significant advances in early diagnosis and treatment in the last decade. It is important to provide updated information regarding these changing demographics as they also reflect a considerable improvement in survival. We analyzed the National Inpatient Sample Database (NIS) in the United States for all patients in which CF was the primary discharge diagnosis (ICD-9: 277.0-277.09) from 2003 to 2013 to evaluate the rate of hospitalizations and determine the cost and mortality associated with CF along with other epidemiological findings. The statistical significance of the difference in the number of hospital discharges, lengths of stays and associated hospital costs over the study period was calculated. In 2003, there were 8,328 hospital discharges with the principal discharge diagnosis of CF in the United States, which increased to 12,590 discharges in 2013 (p < 0.001). The mean hospital charges increased by 57.64% from US$ 60,051 in 2003 to US$ 94,664 in 2013. The aggregate cost of hospital visits increased by 138.31% from US$ 500,105,727 to US$ 1,191,819,760. In the same time, the mortality decreased by 49.3 %. The number of inpatient discharges related to CF has increased from 2003 to 2013. This is due to increased life expectancy of CF patients, resulting in increased disease prevalence. There has been a significant increase in the mean and aggregate cost associated with CF admissions. Over the last decade, many advances have been made in the diagnosis and treatment of CF, consequentially leading to a significant transformation in the epidemiology and demographics of this chronic disease. Rising hospital costs associated with the care of CF patients necessitates future studies analyzing the diagnostic modalities, algorithms and treatment practices of physician's treating CF patients.
AB - Cystic fibrosis (CF) is a multisystem autosomal recessive genetic disorder with significant advances in early diagnosis and treatment in the last decade. It is important to provide updated information regarding these changing demographics as they also reflect a considerable improvement in survival. We analyzed the National Inpatient Sample Database (NIS) in the United States for all patients in which CF was the primary discharge diagnosis (ICD-9: 277.0-277.09) from 2003 to 2013 to evaluate the rate of hospitalizations and determine the cost and mortality associated with CF along with other epidemiological findings. The statistical significance of the difference in the number of hospital discharges, lengths of stays and associated hospital costs over the study period was calculated. In 2003, there were 8,328 hospital discharges with the principal discharge diagnosis of CF in the United States, which increased to 12,590 discharges in 2013 (p < 0.001). The mean hospital charges increased by 57.64% from US$ 60,051 in 2003 to US$ 94,664 in 2013. The aggregate cost of hospital visits increased by 138.31% from US$ 500,105,727 to US$ 1,191,819,760. In the same time, the mortality decreased by 49.3 %. The number of inpatient discharges related to CF has increased from 2003 to 2013. This is due to increased life expectancy of CF patients, resulting in increased disease prevalence. There has been a significant increase in the mean and aggregate cost associated with CF admissions. Over the last decade, many advances have been made in the diagnosis and treatment of CF, consequentially leading to a significant transformation in the epidemiology and demographics of this chronic disease. Rising hospital costs associated with the care of CF patients necessitates future studies analyzing the diagnostic modalities, algorithms and treatment practices of physician's treating CF patients.
KW - Cystic Fibrosis
KW - Epidemiology
KW - Healthcare burden
KW - Hospitalizations
KW - Length of stay
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85028639100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028639100&partnerID=8YFLogxK
U2 - 10.5582/irdr.2017.01043
DO - 10.5582/irdr.2017.01043
M3 - Article
AN - SCOPUS:85028639100
SN - 2186-3644
VL - 6
SP - 191
EP - 198
JO - Intractable and Rare Diseases Research
JF - Intractable and Rare Diseases Research
IS - 3
ER -